Saito, Haruhiro
Kanagawa Cancer Center
4 papers on CoChatORCID 0000-0002-8541-8339
Most cited papers
- Verified
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2019) · The Lancet
Lung Cancer Research StudiesCancer Immunotherapy and Biomarkers
Cited by 2,298
- Verified
Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study
Johnson, M. L., Cho, B. C., Luft, A., Alatorre-Alexander, J., Geater, S. L., Laktionov, K., Kim, S.-W., Ursol, G., Hussein, M., Lim, F. L., et al. (2023) · Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 463
- Verified
Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026
Furuya, N., Fukuhara, T., Saito, H., Watanabe, K., Sugawara, S., Iwasawa, S., Tsunezuka, Y., Yamaguchi, O., Okada, M., Yoshimori, K., et al. (2018) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 59
- Verified
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial
Shiraishi, Y., Kishimoto, J., Sugawara, S., Mizutani, H., Daga, H., Azuma, K., Matsumoto, H., Hataji, O., Nishino, K., Mori, M., et al. (2024) · JAMA Oncology
Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers
Cited by 54
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free